Form 8-K - Current report:
SEC Accession No. 0001140361-25-011181
Filing Date
2025-03-31
Accepted
2025-03-31 08:26:43
Documents
15
Period of Report
2025-03-31
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20046473_8k.htm   iXBRL 8-K 29866
2 EXHIBIT 99.1 ef20046473_ex99-1.htm EX-99.1 173527
6 image0.jpg GRAPHIC 191735
  Complete submission text file 0001140361-25-011181.txt   622280

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ird-20250331.xsd EX-101.SCH 3976
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250331_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250331_pre.xml EX-101.PRE 16041
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20046473_8k_htm.xml XML 4051
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 25789053
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)